Navigation Links
ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine
Date:2/11/2011

THOUSAND OAKS, Calif., Feb. 11, 2011 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries. (www.biocentury.com)

The publication noted that, ImmunGene's CEO Sanjay Khare "anticipates licensing deals will be a key part of ImmunGene's strategy. 'We see a potential model where we out-license our cytokine payload technology and in-license antibodies or antibody targets that will deliver the payload to treat cancer and perhaps other diseases,' he said."

Dr. Sanjay Khare also said, "We are pleased to receive recognition from a global biotech publication for ImmunGene's interferon payload technology and pipeline of next generation of armed antibodies for cancer. Our platform technology, available for non-exclusive licensing, offers the possibility of lower doses of drug for clinical efficacy which will result in the lower cost of goods along with patient convenience and may reduce hospitalization cost."

"We are in advanced discussions with several biotech/pharma companies for both product and technology partnerships," Dr. Khare added.

About BioCentury

BioCentury Publications, Inc. is internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date in
'/>"/>

SOURCE ImmunGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Web Resource for Interferon Research
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
5. Pinpoint precision: Delivering a biochemical payload to 1 cell
6. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
7. Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE)
8. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
9. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
10. Semiconductor technology for ULSIC and TFT conference
11. Reportlinker Adds Industrial Biotechnology China News 1011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... December 2 NicOx S.A.,(NYSE Euronext Paris: ... agreement with,DSM for the commercial manufacture and ... pharmaceutical ingredient). Naproxcinod is NicOx, lead,investigational product ... Oxide-Donating (CINOD) class of,anti-inflammatory agents, which recently ...
... (Pink Sheets: CGCP), a leading developer of surgical products used ... announced the addition of veteran medical device executive and an ... of the Company,s Board of Directors, increasing the number of ... Mr. Cohen, 49, has over 25 years of executive ...
... SHANGHAI, China, Dec. 2 /PRNewswire-Asia/ -- WuXi PharmaTech ... pharmaceutical, biotechnology and medical device,research and development outsourcing ... today announced it will dedicate its Philadelphia facility ... cell therapy,services, and as of December 31, 2008, ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 2WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 4WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 5
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... How,s this for precision? Researchers with the University of ... knock single atoms off a silicon wafer without disturbing ... engineering professor Vince Donnelly and Demetre Economou, Hugh Roy ... same department, are supported in this project by an ...
... to share knowledge, projects and developments in ... creation of synergies and possible frameworks for ... and institutions that address this matter. ... and will be open untill November 11th., ...
... at the National Science Foundation (NSF)--working cooperatively with ... field science supported by the U.S. Antarctic Program, ... to the maximum extent possible, following the October ... a Presidential mandate to manage the U.S. Antarctic ...
Cached Biology News:Creating smaller, and more powerful, integrated circuits 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 3
... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... has been determined, the challenge is to ... audience of scientists, educators and students. Current ... over the Internet, either via online journals ... literature has the advantage of wide acceptance ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: